ACSL4 and acute myeloid leukemia: A multi-cohort validation strategy - filtering 50 discovery candidates (29 testable in BeatAML) through <i>ex vivo</i> drug-response data in 476 primary AML specimens and clinical outcomes in 140 adults with <i>de novo</i> AML (TCGA-LAML) - converged on a single axis linking SRC family kinase inhibition to <i>ACSL4</i> expression.